1h Free Analyst Time
Smoothened Homolog - Pipeline Review, H1 2020Speak directly to the analyst to clarify any post sales queries you may have.
Summary
Smoothened Homolog (Protein Gx or SMO) pipeline Target constitutes close to 14 molecules. Out of which approximately 11 molecules are developed by companies and remaining by the universities/institutes. The latest report Smoothened Homolog - Pipeline Review, H1 2020, outlays comprehensive information on the Smoothened Homolog (Protein Gx or SMO) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.
Smoothened Homolog (Protein Gx or SMO) - Smoothened homolog (SMO) is a G protein-coupled receptor that probably associates with the patched protein (PTCH) to transduce the hedgehog's proteins signal. Binding of sonic hedgehog (SHH) to its receptor is thought to prevent normal inhibition by patched of smoothened (SMO). It is required for the accumulation of KIF7 and GLI3 in the cilia. The molecules developed by companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 3, 2, 3 and 1 respectively.
Similarly, the universities portfolio in Preclinical and Discovery stages comprises 2 and 1 molecules, respectively. Report covers products from therapy areas Oncology, Immunology, Musculoskeletal Disorders and Undisclosed which include indications Adenocarcinoma Of The Gastroesophageal Junction, Gorlin Syndrome (Basal Cell Nevus Syndrome/ Nevoid Basal Cell Carcinoma Syndrome), Medulloblastoma, Basal Cell Carcinoma (Basal Cell Epithelioma), Glioblastoma Multiforme (GBM), Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Breast Cancer, Chronic Myelomonocytic Leukemia (CMML), Colon Cancer, Colorectal Cancer, Epithelial Ovarian Cancer, Esophageal Cancer, Fallopian Tube Cancer, Fibrosis, Graft Versus Host Disease (GVHD), Leukemia, Lung Cancer, Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Myelodysplastic Syndrome, Neuroendocrine Cancer, Non-Small Cell Lung Cancer, Peritoneal Cancer, Prostate Cancer, Small-Cell Lung Cancer, Triple-Negative Breast Cancer (TNBC) and Unspecified.
Furthermore, this report also reviews key players involved in Smoothened Homolog (Protein Gx or SMO) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape for Smoothened Homolog (Protein Gx or SMO)
- The report reviews Smoothened Homolog (Protein Gx or SMO) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Smoothened Homolog (Protein Gx or SMO) targeted therapeutics and enlists all their major and minor projects
- The report assesses Smoothened Homolog (Protein Gx or SMO) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Smoothened Homolog (Protein Gx or SMO) targeted therapeutics
Reasons to Buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Smoothened Homolog (Protein Gx or SMO)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Smoothened Homolog (Protein Gx or SMO) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
- Introduction
- Report Coverage
- Smoothened Homolog (Protein Gx or SMO) - Overview
- Smoothened Homolog (Protein Gx or SMO) - Therapeutics Development
- Products under Development by Stage of Development
- Products under Development by Therapy Area
- Products under Development by Indication
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Smoothened Homolog (Protein Gx or SMO) - Therapeutics Assessment
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Smoothened Homolog (Protein Gx or SMO) - Companies Involved in Therapeutics Development
- Alfasigma SpA
- F. Hoffmann-La Roche Ltd
- Genentech Inc
- Guangdong Zhongsheng Pharmaceutical Co Ltd
- IMPACT Therapeutics Inc
- Mayne Pharma Group Ltd
- PellePharm Inc
- Pfizer Inc
- Sun Pharma Advanced Research Company Ltd
- Suzhou Kintor Pharmaceutical Inc
- Smoothened Homolog (Protein Gx or SMO) - Drug Profiles
- glasdegib - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- GSA-10 - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- GT-1708 - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- IMP-5471 - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- itraconazole - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- patidegib - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- Small Molecule to Antagonize SMO and HDAC for Oncology - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- Small Molecule to Antagonize SMO for Colon Cancer and Medulloblastoma - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- Small Molecules to Antagonize SMO for Colorectal Cancer - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- Small Molecules to Inhibit Smoothened Homolog for Oncology - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- Smoothened Homolog (Protein Gx or SMO) - Dormant Products
- Smoothened Homolog (Protein Gx or SMO) - Discontinued Products
- Smoothened Homolog (Protein Gx or SMO) - Product Development Milestones
- Featured News & Press Releases
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact Us
- Disclaimer
List of Tables
- Number of Products under Development by Stage of Development, H1 2020
- Number of Products under Development by Therapy Areas, H1 2020
- Number of Products under Development by Indications, H1 2020
- Number of Products under Development by Indications, H1 2020 (Contd..1), H1 2020
- Number of Products under Development by Companies, H1 2020
- Products under Development by Companies, H1 2020
- Products under Development by Companies, H1 2020 (Contd..1), H1 2020
- Number of Products under Investigation by Universities/Institutes, H1 2020
- Products under Investigation by Universities/Institutes, H1 2020
- Number of Products by Stage and Mechanism of Actions, H1 2020
- Number of Products by Stage and Route of Administration, H1 2020
- Number of Products by Stage and Molecule Type, H1 2020
- Pipeline by Alfasigma SpA, H1 2020
- Pipeline by F. Hoffmann-La Roche Ltd, H1 2020
- Pipeline by Genentech Inc, H1 2020
- Pipeline by Guangdong Zhongsheng Pharmaceutical Co Ltd, H1 2020
- Pipeline by IMPACT Therapeutics Inc, H1 2020
- Pipeline by Mayne Pharma Group Ltd, H1 2020
- Pipeline by PellePharm Inc, H1 2020
- Pipeline by Pfizer Inc, H1 2020
- Pipeline by Sun Pharma Advanced Research Company Ltd, H1 2020
- Pipeline by Suzhou Kintor Pharmaceutical Inc, H1 2020
- Dormant Products, H1 2020
- Dormant Products, H1 2020 (Contd..1), H1 2020
- Dormant Products, H1 2020 (Contd..2), H1 2020
- Dormant Products, H1 2020 (Contd..3), H1 2020
- Discontinued Products, H1 2020
List of Figures
- Number of Products under Development by Stage of Development, H1 2020
- Number of Products under Development by Therapy Areas, H1 2020
- Number of Products under Development by Top 10 Indications, H1 2020
- Number of Products by Stage and Mechanism of Actions, H1 2020
- Number of Products by Routes of Administration, H1 2020
- Number of Products by Stage and Routes of Administration, H1 2020
- Number of Products by Stage and Molecule Type, H1 2020
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Alfasigma SpA
- F. Hoffmann-La Roche Ltd
- Genentech Inc
- Guangdong Zhongsheng Pharmaceutical Co Ltd
- IMPACT Therapeutics Inc
- Mayne Pharma Group Ltd
- PellePharm Inc
- Pfizer Inc
- Sun Pharma Advanced Research Company Ltd
- Suzhou Kintor Pharmaceutical Inc
